Reference number : 236-2016-2017-Q2-00652, amendment number : , agreement type : G, recipient legal name : Coutts, Shelagh B, recipient country : CA, recipient province : AB, recipient city : Calgary, recipient postal code : T2N 1N4, program name english : nan, program name french : nan, program purpose english : nan, program purpose french : nan, agreement title english : nan, agreement title french : nan, agreement number : nan, agreement value : 100000.0, agreement start date : 2016-07-01, agreement end date : 2017-06-30, description english : TEMPO-2 - Multicentre, prospective randomized open label, blinded-endpoint (PROBE) controlled trial of thrombolysis with low dose Tenecteplase (TNK-tPA) versus standard of care in the prevention of disability at 3 months in minor ischemic stroke with proven acute symptomatic occlusion., description french : TEMPO-2 - Multicentre, prospective randomized open label, blinded-endpoint (PROBE) controlled trial of thrombolysis with low dose Tenecteplase (TNK-tPA) versus standard of care in the prevention of disability at 3 months in minor ischemic stroke with proven acute symptomatic occlusion., expected results english : nan, expected results french : nan, additional information english : Grant or Award spanning more than one fiscal year.
(2016-17 to 2017-18), additional information french : Subvention ou bourse octroyée s'appliquant à plus d'un exercice financier.
(2016-17 à 2017-18), owner organization : cihr-irsc, owner organization title : Canadian Institutes of Health Research | Instituts de recherche en santé du Canada